Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Principal Investigator
Name
Barry Kramer
Institution
NIH Office of Disease Prevention
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2006-0010
Initial CDAS Request Approval
Jul 1, 2006
Title
Cumulative Incidence of False-Positive Screening Test and Resulting Risks of Adverse Events in the PLCO Trial
Summary
Multiple cancer screening tests have been advocated for the general population. However, providers and patients are not always well-informed of the burdens incurred by screening. We sought to determine the cumulative risk of a false positive (FP) screen, and resulting diagnostic procedure risk, for an individual in a multiple modality screening program. Methods Data were analyzed for a 3-year period from the intervention arm of the randomized PLCO Cancer Screening Trial. Eligible individuals were 55 to 74 years of age with no prior history of prostate, lung, colorectal, or ovarian cancer. Additional exclusion criteria were: 1) death before/refusal to take/missing all screens, and 2) less than 3-year follow-up. 68,415 participants were included. The control arm received "usual care." Women randomized to screening were offered annual CA-125, transvaginal ultrasound, CXR, and baseline plus 3- or 5-year sigmoidoscopy (FSG). Men randomized to screening were offered annual digital rectal exam, PSA, CXR, and baseline plus 3- or 5-year FSG. Fourteen exams were possible for each sex over the study period. We defined a FP as a positive screen with no target cancer diagnosis after at least 3-years follow-up. Advanced adenomas (villous histology, severe cellular dysplasia, or =1cm in diameter) were considered true positives. Results 42.6% (N=29,152) of participants had at least one FP. Using a geometric distribution model, the cumulative risk of a FP after 1 screen was 5.7% for men, and 2.2% for women. After 14 tests, the risk was 62.2% for men and 50.7% for women. Sensitivity analysis for FP risk after 14 tests by Kaplan-Meier method demonstrated a cumulative FP risk of 61.5% for men and 54.5% for women. The consequent cumulative risk of a diagnostic procedure was about 27% for men and 18% for women after 14 tests. Conclusions For an individual participating in a multiple modality cancer screening trial, the risk of a FP exceeded 50% by the 14th test. Physicians should educate patients about the risks of FP tests and resulting diagnostic interventions when counseling about cancer screening regimens.
Aims

This study seeks to determine FP rates, and resulting diagnostic procedure rates, for persons enrolled in the PLCO trial. Additionally, using PLCO data, we sought to estimate the cumulative risk of a FP or resulting diagnostic procedure for an individual agreeing to participate in a multi-modality cancer screening program over the course of 14 exams.

Collaborators

S. Baker
Jian-Lun Xu (Division of Cancer Prevention)
Aimee Kreimer (Division of Cancer Prevention)
Jennifer Miller (NIH ODP)
Phil Prorok (Division of Cancer Prevention)

Related Publications